Aripiprazole Tablet
Product Images NDC 43598-965

16 FDA label images from Dr.reddy�s Laboratories Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43598-965). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy�s Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Aripiprazole Structure)

Structural Formula (Aripiprazole Structure)
Chemical structure diagram of aripiprazole showing its molecular framework including two chlorine atoms attached to a phenyl ring, a substituted piperazine ring, and a quinolinone moiety connected by an ether linkage.*
FDA Label Image

Figure-1.jpg (Figure1)

Figure-1.jpg (Figure1)
This chart illustrates the effect of various drugs on Aripiprazole pharmacokinetics, showing change relative to reference (without interacting drug) for AUC and Cmax values. It includes data for CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducer, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam, with fold changes and 90% confidence intervals.*
FDA Label Image

Figure-2.jpg (Figure2)

Figure-2.jpg (Figure2)
A bar chart titled 'Effect of Other Drugs on Aripiprazole' showing the pharmacokinetic impact of various inhibitors, inducers, and other drugs on Aripiprazole's AUC and Cmax. The chart displays fold change and 90% confidence intervals relative to a reference without interacting drugs, depicting increases or decreases in drug exposure.*
FDA Label Image

Figure-3.jpg (Figure3)

Figure-3.jpg (Figure3)
A pharmacokinetic chart titled 'Effect of Aripiprazole on Other Drugs' showing fold changes and 90% confidence intervals for various drugs metabolized by enzymes such as CYP2D6, CYP2C9, UGT1A4, and others. The x-axis represents change relative to reference (without interacting drug), ranging from 0.5 to 3. The chart compares parameters like AUC and Cmax for drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, desmethylvenlafaxine, and escitalopram when coadministered with Aripiprazole.*
FDA Label Image

Figure-4.jpg (Figure4)

Figure-4.jpg (Figure4)
A chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic changes (AUC and Cmax) relative to reference across special populations, including comparisons by CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. Each category is represented with fold change points and 90% confidence intervals plotted on a horizontal axis labeled 'Change Relative to Reference' ranging from 0.5 to 3.0.*
FDA Label Image

Figure-5.jpg (Figure5)

Figure-5.jpg (Figure5)
A scatter plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the fold change and confidence intervals for pharmacokinetic parameters (AUC and Cmax) across different categories including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with the x-axis representing change relative to reference values.*
FDA Label Image

Figure-6.jpg (Figure6)

Figure-6.jpg (Figure6)
A Kaplan-Meier survival curve displaying the proportion of subjects with relapse over days from randomization, comparing Aripiprazole and placebo groups. The x-axis shows days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0.0 to 1.0. The chart includes the number of subjects at risk over time for each group.*
FDA Label Image

Figure 7 (Figure7)

Figure 7 (Figure7)
A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over 182 days from randomization. The chart compares two groups: Aripiprazole (solid line) and Placebo (dashed line). The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Below the x-axis, the number of subjects at risk for each group at specified time points is listed.*
FDA Label Image

Figure 8 (Figure8)

Figure 8 (Figure8)
A line graph comparing the proportion of subjects with relapse over 364 days from randomization between Aripiprazole-treated and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Two lines represent Aripiprazole (solid) and placebo (dashed), with the number of subjects at risk displayed below the x-axis.*
FDA Label Image

Figure-1.jpg (Figure9)

Figure-1.jpg (Figure9)
A line graph depicting the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole Low dose, Aripiprazole High dose, and Placebo. The y-axis shows the least-squares mean change in YGTSS total tic score, with values decreasing from 0 to -20, while the x-axis represents weeks of treatment from 0 to 8. The Aripiprazole groups show a greater reduction in tic scores over time compared to placebo.*
FDA Label Image

2mg-30 (Aripiprazole Label1)

2mg-30 (Aripiprazole Label1)
Label for Aripiprazole Tablets, USP 2 mg, with an NDC of 43598-965-30. The label specifies the tablet strength as 2 mg, package quantity of 30 tablets, and includes pharmacist dispensing instructions. The labeler is Dr. Reddy's Laboratories Inc. Storage instructions and manufacturer details by ScieGen Pharmaceuticals, Inc. and distribution by Dr. Reddy's Laboratories, Inc. are also shown.*
FDA Label Image

5mg-30 (Aripiprazole Label2)

5mg-30 (Aripiprazole Label2)
Label for Aripiprazole Tablets, USP, 5 mg oral tablets. The package contains 30 tablets and is labeled for Rx only. It includes storage instructions and manufacturer information, showing Dr. Reddy's Laboratories, Inc. as the distributor and SciGen Pharmaceuticals, Inc. as the manufacturer. The label also advises the pharmacist to dispense the accompanying Medication Guide to each patient.*
FDA Label Image

10mg-30 (Aripiprazole Label3)

10mg-30 (Aripiprazole Label3)
Label for Aripiprazole Tablets, USP 10 mg oral tablets by Dr. Reddy's Laboratories Inc. The bottle contains 30 tablets. The label includes dispensing instructions for pharmacists, storage conditions, and manufacturer details. The barcode and a 'NO VARNISH' mark are also visible.*
FDA Label Image

15mg-30 (Aripiprazole Label4)

15mg-30 (Aripiprazole Label4)
Label for Aripiprazole Tablets, USP 15 mg oral tablets by Dr. Reddy's Laboratories Inc. The label indicates 30 tablets per container, Rx only, with instructions to dispense the Medication Guide to patients. Storage instructions specify keeping the product in tightly closed containers between 15°C to 30°C (59°F to 86°F). Manufacturer is SciGen Pharmaceuticals, Inc. Bar code and revision date 07/20 are also visible.*
FDA Label Image

20mg-30 (Aripiprazole Label5)

20mg-30 (Aripiprazole Label5)
Label for Aripiprazole Tablets, USP 20 mg by Dr. Reddy's Laboratories Inc. The label specifies a bottle of 30 oral tablets, prescription-only, with storage instructions and usual dosage guidance. It includes the NDC number 43598-969-30 and a barcode. The label also states no varnish overprint on the right side.*
FDA Label Image

30mg-30 (Aripiprazole Label6)

30mg-30 (Aripiprazole Label6)
Label for Aripiprazole Tablets USP 30 mg, oral tablets produced by Dr. Reddy's Laboratories Inc. The label indicates a package size of 30 tablets and includes storage instructions, dosage guidance, and barcode. The label features the brand name prominently with an emphasis on 30 mg strength.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.